NitroMed, Inc. to Hold First Quarter 2005 Financial Results Conference

    Business Editors/Medical Editors
    BIOWIRE2K

    LEXINGTON, Mass.--(BUSINESS WIRE)--April 28, 2005--NitroMed, Inc. (NASDAQ: NTMD) today announced that it will host a conference call to discuss 2005 first quarter financial results on Thursday, May 5, 2005 at 5:00 pm Eastern Time.
    This conference call will be webcast and can be accessed live or via archive for seven days on NitroMed's website at www.nitromed.com.
    In the United States, the call can also be accessed by dialing 800-299-9086. The international dial in number is 617-786-2903. The participant pass code is 27884303 for both numbers.
    An audio replay of the call will be available two hours after the call by dialing 888-286-8010 in the US and 617-801-6888 internationally. The replay pass code is 48136455 for both numbers.

    About NitroMed, Inc.

    NitroMed is an emerging pharmaceutical company focused on the research, development and commercialization of proprietary pharmaceuticals based on the therapeutic benefits of the naturally occurring molecule nitric oxide. The Company uses its expertise in nitric oxide biology and chemistry in an effort to develop both new pharmaceuticals, as well as safer, more effective versions of existing drugs. Research and development efforts focus on major diseases that are characterized by a deficiency in nitric oxide, such as cardiovascular and inflammatory diseases. BiDil, the Company's lead product candidate, is an orally administered nitric oxide-enhancing medicine being developed for the treatment of heart failure in African Americans. Corporate collaborations are also an element of the Company's business strategy, and NitroMed has an agreement with Boston Scientific to jointly develop nitric oxide-enhanced cardiovascular stents.

    Forward Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, including statements regarding the Company's plans and expectations regarding its drug candidate BiDil, its development plans for other nitric-oxide enhancing medicines, as well as statements containing the words "believe," "anticipate," "plan," "expect," "will," "may," "seek," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: difficulties or delays relating to required regulatory approvals to develop, market and sell BiDil and the Company's other products under development; the Company's ability to successfully complete clinical trials of its products under development; the Company's dependence on corporate collaborators to develop, manufacture, market and sell products based upon its technologies; the Company's failure to obtain or maintain intellectual property protection and required licenses for its technologies and products under development; the Company's ability to obtain the substantial additional funding required to conduct research and development, manufacturing, marketing and sales of its products under development; and other factors discussed in its Annual Report on Form 10-K for the year ended December 31, 2004, which is filed with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

--30--JO/bo*

CONTACT: NitroMed, Inc. Lawrence E. Bloch, M.D., J.D., 781-266-4197 Chief Financial Officer and Chief Business Officer

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: NitroMed, Inc.

Copyright Business Wire 2005